Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is an exploratory study to study the efficacy of combination regimen of
Oncaspar/Doxil/Decadron (ODD) in patients with refractory lymphoid malignancies. Patients
with any form of lymphoid malignancy will be eligible: acute lymphoblastic leukemia, chronic
lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma and plasma
cell leukemia. Patients must have failed standard regimens for their cancers and could have
had unlimited number of prior regimens. Patients will be staged appropriately for their
disease with clinical examination, laboratory tests, and imaging studies. Both Oncaspar and
Doxil will be given on day 1 and 15. Patients will be clinically evaluated prior to each
cycle and will have disease assessments every 2 cycles. Responding patients will continue
therapy until disease progression or excessive toxicity. Responders who are candidates for
allogenic stem cell transplantation could go to conditioning chemotherapy and stem cell
transplant after 4 cycles of ODD.